Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Ранг среди акций #29513
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Цена акции
$0.12952814
Рыночная капитализация
$21.11M
Изменение (1 день)
4.40%
Изменение (1 год)
-35.74%
Страна
FR
Торговля GenSight Biologics S.A. (SIGHT)

Категория

История цены акций GenSight Biologics S.A. (SIGHT)
Наивысшая цена закрытия: $0.11 2026-08-01

Наименьшая цена закрытия: $8.93 2016-07-01
История цены акций GenSight Biologics S.A. с 2016 по 2026
Годовая динамика цены акций
Год Результативность
2026 (TTM) 0.84%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
$544.11 39.24%
US
$1.02K 56.01%
NL
$144.46 417.59%
US
$117.42 -19.34%
AU
$754.32 8.74%
CH